From:  Immune checkpoint inhibitors in patients with advanced gastric cancer: a multi-institutional retrospective real-world study

Treatment response in the low NLR group and high NLR group

ResponseNLR < 1.8
n, %		NLR ≥ 1.8
n, %		P
N1732
CR1 (6)0 (0)0.159
PR5 (29)1 (3)0.008
SD6 (35)11 (34)0.949
PD5 (29)20 (62)0.70
ORR6 (35)1 (3)0.002
DCR12 (71)12 (38)0.027
Return to article view

NLR: neutrophil-lymphocyte ratio; objective response rate (ORR) = complete response (CR) + partial response (PR); disease control rate (DCR) = CR + PR + stable disease (SD); PD: progressive disease